New to AVXL? Nov. 7 is the crucial day for us -- e
Post# of 1460
Posted On: 10/31/2015 11:26:47 AM
New to AVXL? Nov. 7 is the crucial day for us -- even though it's a Saturday. AVXL reports then on the Phase 2A of their Alzheimer's study. Preliminary data with the first 12 patients showed a cognitive improvement after 30 days of the drug. Those patients petitioned to be allowed to continue taking the drug (granted), and these results will tell us the results for the next batch of 20 more patients. They initially titled their talk "Cognitive IMPROVEMENT in...." but then the title was changed. There's been a lot of speculation about the title change, but a likely theory is that the conference embargoes actual results being PR'ed until the day of the talk.
Given that the company was able to snag one of the few "late-breaking results" slots at the conference, and that it's a talk, not a poster presentation, the odds are good that the initial title "Cognitive Improvement" is telling us what they're going to say.
Given that the company was able to snag one of the few "late-breaking results" slots at the conference, and that it's a talk, not a poster presentation, the odds are good that the initial title "Cognitive Improvement" is telling us what they're going to say.
(0)
(0)Anavex Life Sciences Corp. (AVXL) Stock Research Links
Scroll down for more posts ▼